OakChart

Autolus Therapeutics plc ADR

AUTLHealthcare·Biotechnology·United Kingdom·Small·NASD·Nov 11 • 2:54 PM ET

1.27-0.05 (-3.79%)
2026-11-11 20:54 CET
Market cap
351.34 USD m
Revenue, TTM
137.42 USD m
Net income, TTM
-255.92 USD m
Free cash flow, TTM
- USD m
EPS diluted, TTM
-0.96
P/E
-
Compare

Price

AUTL against its 20, 50 and 200-day averages
2050200beatmiss
1.502.002.506.7M13.4MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26AUTLclose 1.2720-day 1.4950-day 1.74200-day 1.661.2752w high52w low

50.8% under the 52-week high of 2.58 on 19 Aug 2026. 52-week low 1.12 on 10 Nov 2026. Last 15 sessions, 47.3% high to low

Profile

AUTL
52-week range, 10% of the way up
1.122.58

Autolus Therapeutics Plc is a biopharmaceutical company, which engages in the development and commercialization of gene therapies. It uses proprietary and modular T cell programming technologies that are designed to recognize cancer cells, break down their defense mechanisms, and attack and kill these cells. The company was founded by Martin Pule in September 2014 and is headquartered in London, the United Kingdom.

Employees752
IPOJun 22, 2018
Beta2.36
ATR, 14d0.12
Rel volume1.80
Short float3.59%
Insider own9.63%
Inst own45.97%

Snapshot

6 groups

Valuation

Index-
Market Cap338.02M
Enterprise Value457.45M
Income-255.92M
Sales137.42M
Book/sh0.21
Cash/sh0.93
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees752
IPOJun 22, 2018

Ratios

P/E-
Forward P/E-
PEG-
P/S2.46
P/B6.03
P/C1.36
P/FCF-
EV/EBITDA-
EV/Sales3.33
Quick Ratio4.36
Current Ratio3.72
Debt/Eq0.74
LT Debt/Eq0.70
Option/ShortYes / Yes

Earnings

EPS (ttm)-0.96
EPS next Y-0.63
EPS next Q-0.17
EPS this Y25.06%
EPS next Y21.85%
EPS next 5Y26.65%
EPS past 3/5Y11.57% 17.04%
Sales past 3/5Y130.25% 215.43%
EPS Y/Y TTM-21.91%
Sales Y/Y TTM167.93%
EPS Q/Q29.99%
Sales Q/Q95.70%
EarningsNov 10 BMO
EPS/Sales Surpr.-29.31% 4.30%

Ownership

Insider Own9.63%
Insider Trans-0.03%
Inst Own45.97%
Inst Trans-2.26%
ROA-43.19%
ROE-67.25%
ROIC-60.37%
Gross Margin41.59%
Oper. Margin-159.52%
Profit Margin-186.24%
SMA20-14.72%
SMA50-27.12%
SMA200-23.58%
Trades-

Technical

Shs Outstand266.16M
Shs Float240.53M
Short Float3.59%
Short Ratio3.88
Short Interest8.63M
52W High2.58 -50.78%
52W Low1.12 13.39%
Volatility11.55% 7.59%
ATR (14)0.12
RSI (14)29.15
Beta2.36
Rel Volume1.80
Avg Volume2.22M
Volume3,354,835

Performance

Perf Week-7.97%
Perf Month-21.60%
Perf Quarter-42.79%
Perf Half Y-25.73%
Perf YTD-36.18%
Perf Year-15.33%
Perf 3Y-62.97%
Perf 5Y-81.19%
Perf 10Y-
Recom1.00
Target Price8.49
Prev Close1.32
Price1.27
Change %-3.79%

Analyst ratings

latest 10 of 16
DateActionAnalystRating changeTargetImplied
Nov 02, 2026ResumedHH.C. WainwrightBuy$10+687.4%
Feb 17, 2026InitiatedHH.C. WainwrightBuy$9+608.7%
Nov 18, 2024UpgradeGGoldmanNeutral → Buy$7 → $7.60+498.4%
Nov 15, 2024UpgradeRRedburn AtlanticNeutral → Buy$13+923.6%
Nov 09, 2023InitiatedDDeutsche BankBuy$10+687.4%
Mar 27, 2023ResumedWWells FargoOverweight$8+529.9%
Mar 17, 2023InitiatedBBryan GarnierBuy$5+293.7%
Jun 14, 2021UpgradeJJefferiesHold → Buy$6 → $12+844.9%
Jan 29, 2021DowngradeJJP MorganOverweight → Neutral$9+608.7%
Dec 28, 2020ResumedHH.C. WainwrightBuy$19+1,396.1%

Peers

Mkt cap
TickerCompanyMkt cap
ALLOAllogene Therapeutics Inc317.95M
LEGNLegend Biotech Corp ADR3.72B
CABACabaletta Bio Inc326.81M
KYTXKyverna Therapeutics Inc319.11M
GILDGilead Sciences Inc210.49B
FATEFate Therapeutics Inc198.77M
CRBUCaribou Biosciences Inc42.16M
NVSNovartis AG ADR292.83B
SANASana Biotechnology Inc701.80M
NKTXNkarta Inc107.20M

Insider trading

3 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Piccina CintiaU.S. CCO & Country Gen ManagerSep 01 '26Option Exercise2.3520,00047,00020,000Sep 03 04:36 PM
Piccina CintiaU.S. CCO & Country Gen ManagerSep 02 '26Sale2.346,71315,68213,287Sep 03 04:36 PM
Piccina CintiaOfficerSep 02 '26Proposed Sale2.346,71315,679Sep 02 03:31 PM

Held by

AUM
TickerCompanyAUM
IBBiShares Biotechnology ETFAUM: 11.36B
CANCTema Oncology ETFAUM: 217.09M
GWXState Street SPDR S&P International Small Cap ETFAUM: 906.57M
QQQSInvesco NASDAQ Future Gen 200 ETFAUM: 20.53M
APIEActivePassive International Equity ETFAUM: 1.13B
IBBQInvesco Nasdaq Biotechnology ETFAUM: 130.27M
BIBProShares Ultra Nasdaq Biotechnology 2X SharesAUM: 107.35M

News

latest 14 of 200
  • Autolus Therapeutics Presents Longer-Term Follow Up Data from CARLYSLE Trial at the American College of Rheumatology Convergence 2026 (GlobeNewswire)
  • Autolus Beats On Revenue And Lifts Its Aucatzyl Outlook, But A Sequential Sales Dip And A Delayed MS Readout Complicate The Story (Earnings Whispers)
  • Autolus Therapeutics Reports Third Quarter 2026 Financial Results and Business Updates (GlobeNewswire)
  • Autolus Therapeutics to Participate in the Jefferies Global Healthcare Conference (GlobeNewswire)
  • Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2026 (GlobeNewswire)
  • Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
  • Autolus Faces A Credibility Test On Obe-Cel Momentum As Shares Slide Below Range Lows (Earnings Whispers) -6.58%
  • Autolus Therapeutics to Report Third Quarter 2026 Financial Results and Host Conference Call on November 10, 2026 (GlobeNewswire)
  • Autolus Therapeutics to Present Longer-Term Follow Up Data from CARLYSLE Trial at the American College of Rheumatology Convergence 2026 (GlobeNewswire)
  • Autolus Therapeutics Announces FDA RMAT Designation Granted to Obe-cel for the Treatment of Systemic Lupus Erythematosus and Lupus Nephritis (GlobeNewswire)
  • Autolus shares rise as Q2 beat and higher AUCATZYL guidance signal launch momentum (InvestorsHub) +12.56%
  • Autolus Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates (GlobeNewswire)
  • Autolus Therapeutics to Report Second Quarter 2026 Financial Results and Host Conference Call on August 11, 2026 (GlobeNewswire) +22.15% +7.14%
  • Autolus Therapeutics Reports Preliminary Second Quarter 2026 Net Product Revenue and Announces Credit Facility of up to $250 Million with Perceptive Advisors (GlobeNewswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-10-0.210-0.162-0.20741.2439.547
2026Q22026-08-11-0.150-0.194-0.14745.6938.567
2026Q12026-05-14-0.270-0.253-0.26926.2226.278
2025Q42026-03-27-0.340-0.260-0.33924.2923.929
2025Q32025-11-12-0.300-0.214-0.29521.5922.068
2025Q22025-08-12-0.180-0.231-0.18220.9213.248
2025Q12025-05-08-0.260-0.244-0.2658.992.237
2024Q42025-03-20-0.090-0.206-0.1030.022.897
2024Q32024-11-12-0.310-0.214-0.3120.000.167
2024Q22024-08-08-0.220-0.195-0.2190.000.097
2024Q12024-05-17-0.240-0.080-0.23710.0929.017
2023Q42024-03-14-0.426-0.253-0.4470.000.368
2023Q32023-11-02-0.260-0.250-0.2640.340.627
2023Q22023-08-03-0.260-0.224-0.2620.000.148
2023Q12023-05-04-0.230-0.267-0.2291.250.388
2022Q42023-03-07-0.238-0.269-0.2303.8211.188

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-2.880-2.697-2.8762.913.12
2020FY-2.760-2.667-2.7561.471.55
2021FY-1.970-1.821-1.9710.8212.19
2022FY-1.570-1.580-1.5666.3613.54
2023FY-1.200-1.008-1.2031.701.95
2024FY-0.860-0.901-0.86510.1215.66
2025FY-1.080-0.985-1.08075.3975.91
2026FY--0.809--150.84
2027FY--0.633--203.34
2028FY--0.426--287.26
2029FY--0.137--457.82
2030FY-0.135--593.43

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-1072138.2632.0040.72
2026Q4S2026-10-2870137.9032.0040.52
2026Q4S2026-10-2570237.9032.0040.52
2026Q4S2026-10-1573437.9032.0040.52
2026Q4S2026-09-2973438.3732.0043.50
2026Q4S2026-09-0873438.3732.0043.50
2026Q4S2026-08-2873438.3732.0043.50
2026Q4S2026-08-1473438.3732.0043.50
2026Q4S2026-08-1173338.9436.0043.50
2026Q4S2026-07-3172138.2234.5244.20
2026Q4S2026-07-2870036.9734.5242.02
2026Q4S2026-07-1073236.9734.5242.02
2026Q4S2026-06-2573236.9734.5242.02
2026Q4S2026-05-1483237.3034.5242.02

Estimate history

EPS, annual-0.491-1.418-2.876-2.756-1.971-1.566-1.203-0.865-1.083-0.9616
Period201720182019202020212022202320242025TTM
EPS, quarterly-0.312-0.103-0.265-0.182-0.295-0.339-0.269-0.147-0.207
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual0000.2421.5076.191.70510.12475.564137.42
Period201720182019202020212022202320242025TTM
Sales, quarterly00.0299.01621.18221.06224.25426.17445.77241.218
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual40.14640.14644.98352.34690.908173.075174.101266.125266.143266.163
Period201720182019202020212022202320242025MRQ
Shares, quarterly266.119266.125266.141266.141266.143266.143266.156266.163-
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue137.4275.5610.121.706.191.510.240.000.00
Cost of Goods Sold Incl. D&A80.2796.5919.116.597.42--4.611.71
Gross Profit57.15-21.03-8.99-4.89-1.23---4.61-1.71
Selling, General and Administrative Excl. Other268.38260.41212.20190.90166.33158.11164.11140.2657.23
Research and Development115.59128.59118.79150.56141.87134.70134.80105.4236.15
Other Operating Expense-0.000.000.000.000.000.000.000.00
Operating Income-219.20-281.44-221.18-195.78-167.56-165.15-169.62-144.87-58.94
Interest Expense-36.769.3045.248.901.100.000.000.00
Unusual Expense-0.350.410.380.000.000.004.10-
Net Income Before Taxes-256.27-296.85-199.52-228.79-173.06-165.99-166.26-139.01-52.03
Income Taxes-0.34-8.6521.24-19.59-24.31-23.89-24.16-15.16-7.28
Consolidated Net Income-255.92-288.20-220.75-209.19-148.75-142.10-142.09-123.85-44.75
Net Income From Continuing Operations-255.92-288.20-220.75-209.19-148.75-142.10-142.09-123.85-44.75
Net Income-255.92-288.20-220.75-209.19-148.75-142.10-142.09-123.85-44.75
EPS (Recurring)-0.96-1.08-0.86-1.20-1.57-1.97-2.76-2.81-1.42
EPS (Basic, Before Extraordinaries)-0.96-1.08-0.87-1.20-1.57-1.97-2.76-2.88-1.42
EPS (Diluted)-0.96-1.08-0.87-1.20-1.57-1.97-2.76-2.88-1.42
EBITDA--271.60-213.46-189.19-160.14-156.60-163.87-140.26-57.23
Non-Operating Income (Expense)-13.0521.6931.3812.623.390.263.369.966.91
Other After Tax Adjustments-0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense-10.8511.618.479.738.0516.2224.615.48
Price To Sales Ratio3.767.0159.23657.1629.16248.251,904.67--
Gross Margin41.59-27.83-88.76-286.63-19.83----
Operating Margin-159.52-372.45-2,184.67-11,485.75-2,706.80-10,958.66-70,090.08--
Net Margin-186.24-381.40-2,180.45-12,272.26-2,402.95-9,429.06-58,716.53--
Shares Outstanding-266.14266.13174.10173.0790.9152.3544.9840.15
Market Capitalization351.34351.34625.381,120.15173.15378.45467.55593.761,189.57

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue41.2245.7726.1724.2521.0621.189.020.03
Cost of Goods Sold Incl. D&A17.9220.5124.5325.2931.8527.1420.3113.34
Gross Profit23.3025.271.65-1.04-10.79-5.96-11.29-13.31
Selling, General and Administrative Excl. Other66.8169.1861.0671.3260.3956.0154.2061.85
Research and Development30.8827.9521.1735.5827.7227.7726.8430.54
Other Operating Expense-0.000.000.000.000.000.000.00
Operating Income-43.51-43.92-59.41-72.36-71.17-61.97-65.49-75.16
Interest Expense--2.6811.1122.8010.45-6.9110.18-
Unusual Expense-0.000.000.350.000.000.000.00
Net Income Before Taxes-55.55-38.72-70.62-91.38-78.10-48.11-68.20-25.90
Income Taxes-0.490.470.86-1.180.530.402.231.45
Consolidated Net Income-55.06-39.18-71.48-90.20-78.62-48.51-70.43-27.35
Net Income From Continuing Operations-55.06-39.18-71.48-90.20-78.62-48.51-70.43-27.35
Net Income-55.06-39.18-71.48-90.20-78.62-48.51-70.43-27.35
EPS (Recurring)-0.21-0.15-0.27-0.34-0.30-0.18-0.26-0.10
EPS (Basic, Before Extraordinaries)-0.21-0.15-0.27-0.34-0.30-0.18-0.26-0.10
EPS (Diluted)-0.21-0.15-0.27-0.34-0.30-0.18-0.26-0.10
EBITDA--41.26-56.72-69.73-67.79-59.58-63.20-73.10
Non-Operating Income (Expense)-12.042.52-0.104.133.536.957.4749.26
Other After Tax Adjustments-0.000.000.000.000.000.000.00
Stock Option Compensation Expense-3.642.672.582.863.432.274.27
Price To Sales Ratio3.763.633.967.018.4620.0745.6061.83
Gross Margin56.5355.206.29-4.29-51.21-28.15-125.21-46,327.76
Operating Margin-105.57-95.95-226.99-298.35-337.93-292.58-726.31-261,600.98
Net Margin-133.59-85.60-273.09-371.90-373.30-229.02-781.13-95,193.46
Shares Outstanding-266.16266.16266.14266.14266.14266.14266.13
Market Capitalization351.34425.85367.28529.62433.81606.80412.49625.38

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments302.21589.45240.34382.76310.68154.09211.43247.09137.07
Short Term Receivables75.2647.3123.6028.9426.1829.6830.529.264.73
Inventories33.214.140.000.000.000.000.000.000.00
Other Current Assets21.8017.719.5812.579.0210.217.302.920.68
Total Current Assets432.49658.61273.52424.28345.88193.98249.26259.28142.48
Net Property, Plant & Equipment128.50105.0595.6558.4252.3289.6851.5713.536.18
Total Investments and Advances0.000.000.000.000.000.000.000.000.00
Intangible Assets19.8112.37-0.000.070.160.250.400.00
Deferred Tax Assets3.563.243.062.081.831.750.41--
Other Assets4.713.453.155.505.478.672.040.000.00
Total Assets589.07782.73375.38490.27405.56294.24303.53273.20148.66
Short Term Debt Incl. Current Port. of LT Debt14.563.005.055.044.453.592.510.000.00
Accounts Payable3.081.970.100.530.432.260.000.000.00
Income Tax Payable-----0.000.39--
Other Current Liabilities55.7955.7839.5840.8023.6727.7822.0817.145.03
Total Current Liabilities73.4460.7444.7446.3728.5533.6324.9817.145.03
Long Term Debt337.02294.23218.81145.1216.5550.5723.710.000.00
Provision for Risks Charges0.000.000.000.000.000.000.00-0.00
Other Liabilities0.480.430.360.1247.140.000.000.601.03
Total Liabilities410.94355.40263.91191.6092.2484.2048.6917.746.06
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity178.13427.32111.47298.67313.32210.03254.84255.47142.60
Total Shareholders Equity178.13427.32111.47298.67313.32210.03254.84255.47142.60
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity178.13427.32111.47298.67313.32210.03254.84255.47142.60
Total Liabilities & Stockholders Equity589.07782.73375.38490.27405.56294.24303.53273.20148.66
Book Value Per Share0.501.200.421.141.741.491.901.981.10
Tangible Book Value Per Share0.591.560.641.733.454.015.666.353.55
Full-Time Employees752647463399327384292166100
Price to Book Ratio6.261.316.212.122.986.016.9431.1531.15
Return on Assets-42.02-38.12-48.33-33.21-40.61-47.54-42.95-21.22-21.58
Return on Equity-95.20-81.94-102.01-48.61-54.30-61.13-48.54-22.48-22.77
Return on Invested Capital-55.94-30.59-63.34-33.52-43.08-54.53-44.46-17.52-13.83
Quick Ratio5.4410.776.119.1512.115.779.9815.1328.31
Current Ratio5.8910.846.119.1512.115.779.9815.1328.31

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income--288.20-220.75-209.19-148.75-142.10-142.09-123.85-44.75
Depreciation-9.847.726.597.428.465.664.611.71
Deferred Taxes & Investment Tax Credit--0.29-0.19-0.99-0.27-0.07-1.34-0.400.00
Other Funds (Non Cash)-46.5330.5357.1528.8211.7118.6134.366.77
Funds from Operations--232.12-182.69-146.44-112.77-122.00-119.17-85.28-36.27
Extraordinary Item-0.000.000.000.000.000.000.000.00
Changes in Working Capital--52.11-23.660.290.544.141.41-16.204.73
Cash from Operating Activities--284.23-206.36-146.15-112.24-117.86-117.76-101.48-31.54
Capital Expenditures--27.20-34.83-11.03-10.83-8.86-14.68-18.67-9.53
Net Assets From Acquisitions-0.000.000.000.000.000.000.00-
Sale of Fixed Assets and Businesses-0.000.000.000.000.000.000.00-
Purchase or Sale of Investments-186.02-359.880.000.000.000.000.000.00
Purchase of Investments--243.19-359.880.000.000.000.000.00-
Sale Or Maturity of Investments-429.210.000.000.000.000.000.000.00
Other Uses-0.000.000.000.000.000.000.000.00
Other Sources-0.000.000.000.000.000.000.00-
Cash from Investing Activities-158.83-394.72-11.03-10.83-8.86-14.68-18.67-9.53
Cash Dividends Paid-0.000.000.000.000.000.000.000.00
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Change in Capital Stock-0.00521.44-0.89153.52234.5774.42108.86156.92
Repurchase of Common Pref Stock-0.000.000.000.000.000.000.000.00
Sale of Common Pref Stock-0.00521.44-0.89153.52234.5774.42108.86156.92
Proceedsfrom Stock Options-0.00520.84-0.91153.40234.4574.42108.86156.92
Issuance or Reduction of Debt, Net-0.0068.360.0069.960.000.000.000.00
Change in Long Term Debt-0.0068.360.0069.960.000.000.000.00
Issuance of Long Term Debt-0.0070.030.0069.960.000.000.000.00
Reduction of Long Term Debt-0.00-1.670.000.000.000.000.000.00
Net Financing Active Other Cash Flow--4.350.000.000.0049.490.000.000.00
Other Financing Activities Uses--4.350.000.000.00-0.510.000.000.00
Cash from Financing Activities--4.35589.80-0.89223.47284.0674.42108.86156.92
Exchange Rate Effect-6.29-0.2615.09-28.36-0.750.685.16-5.83
Net Change in Cash--123.46-11.53-142.9872.04156.59-57.34-6.12110.02
Free Cash Flow--303.32-228.44-157.18-123.07-126.72-132.44-119.83-40.66

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments248.38203.13230.93302.21368.91455.79
Short Term Receivables-77.0485.7475.2691.3678.05
Inventories-33.4333.2333.2127.7223.94
Other Current Assets-19.8516.3221.8023.2113.61
Total Current Assets366.78333.45366.21432.49511.20571.39
Net Property, Plant & Equipment-134.63134.47128.50123.48125.09
Total Investments and Advances-0.000.000.000.000.00
Intangible Assets-18.5318.9819.8120.2812.93
Deferred Tax Assets-2.793.583.562.392.40
Other Assets-3.823.834.714.609.17
Total Assets523.06493.23527.07589.07661.95720.98
Short Term Debt Incl. Current Port. of LT Debt-18.6914.9614.5612.239.28
Accounts Payable-1.371.873.0810.975.41
Other Current Liabilities98.6548.7346.7755.7959.8853.47
Total Current Liabilities98.6568.7963.6073.4483.0768.15
Long Term Debt-349.12354.16337.02312.95305.89
Provision for Risks Charges-0.000.000.000.000.00
Other Liabilities0.000.470.480.480.470.48
Total Liabilities98.65418.39418.24410.94396.50374.52
Non-Equity Reserves-0.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity495.6674.84108.83178.13265.45346.46
Total Shareholders Equity495.6674.84108.83178.13265.45346.46
Accumulated Minority Interest-0.000.000.000.000.00
Total Equity495.6674.84108.83178.13265.45346.46
Total Liabilities & Stockholders Equity523.06493.23527.07589.07661.95720.98
Book Value Per Share-0.210.310.500.750.98
Tangible Book Value Per Share-0.210.340.590.921.25
Full-Time Employees---752--
Price to Book Ratio6.265.222.752.661.671.64
Return on Assets-43.19-46.04-45.36-41.95-30.20-29.12
Return on Equity-67.25-132.68-120.36-95.06-60.59-52.44
Return on Invested Capital--9.24-15.44-17.51-13.59-7.44
Quick Ratio-4.365.245.445.828.03
Current Ratio3.724.855.765.896.158.38

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income--39.21-71.48-90.29-78.81-48.93
Depreciation-2.652.69-0.153.344.37
Other Funds (Non Cash)-3.7320.0723.3620.25-6.61
Funds from Operations--32.04-48.73-68.26-55.21-50.79
Extraordinary Item-0.000.000.000.000.00
Changes in Working Capital-6.88-16.481.05-12.19-23.27
Cash from Operating Activities--25.16-65.21-67.21-67.40-74.06
Capital Expenditures--0.92-2.680.92-12.46-7.41
Net Assets From Acquisitions-0.000.000.000.000.00
Sale of Fixed Assets and Businesses-0.000.000.000.000.00
Purchase or Sale of Investments-68.9598.6785.7347.96103.64
Purchase of Investments--0.02-14.70-40.22-82.64-49.02
Sale Or Maturity of Investments-68.97113.37125.95130.60152.66
Other Uses-0.000.000.000.000.00
Other Sources-0.000.000.000.000.00
Cash from Investing Activities-68.0395.9986.6535.4996.23
Cash Dividends Paid-0.000.000.000.000.00
Preferred Dividends (Cash Flow)-0.000.000.000.000.00
Change in Capital Stock-0.000.000.000.000.00
Repurchase of Common Pref Stock-0.000.000.000.000.00
Sale of Common Pref Stock-0.000.000.000.000.00
Proceedsfrom Stock Options-0.000.000.000.000.00
Issuance or Reduction of Debt, Net--2.15-2.060.000.000.00
Change in Long Term Debt--2.15-2.060.000.000.00
Issuance of Long Term Debt-0.000.000.000.000.00
Reduction of Long Term Debt--2.15-2.060.000.000.00
Net Financing Active Other Cash Flow-0.000.00-1.80-1.78-0.77
Other Financing Activities Uses-0.000.00-1.80-1.78-0.77
Cash from Financing Activities--2.14-2.06-1.80-1.78-0.77
Exchange Rate Effect--0.20-1.990.58-3.645.79
Net Change in Cash-40.5226.7418.23-37.3327.19
Free Cash Flow--26.08-67.89-66.29-71.75-81.47

Revenue breakdown

Biological Products, (No Diagnostic Substances)2024: 10.12M
Europe2024: 10.12M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-303.59%8.6M240.5M2.26M
2026-10-153.77%9.1M240.5M2.09M
2026-09-303.49%8.4M240.5M2.04M
2026-09-153.46%8.3M240.5M1.97M
2026-08-313.78%9.1M240.5M1.89M
2026-08-144.36%10.5M240.5M1.77M
2026-07-315.73%13.8M240.5M1.33M
2026-07-156.30%15.1M240.5M1.41M
2026-06-305.19%12.5M240.5M1.43M
2026-06-155.60%13.5M240.5M1.59M
2026-05-295.32%12.8M240.5M1.63M
2026-05-155.83%14.0M240.5M1.65M
2026-04-305.45%13.1M240.3M1.57M
2026-04-155.91%14.2M240.3M1.65M
2026-03-316.07%14.6M240.3M1.91M
2026-03-136.11%14.7M240.3M2.02M
2026-02-276.23%15.0M240.3M2.20M
2026-02-136.60%15.9M240.3M2.69M
2026-01-306.42%15.4M240.3M2.90M
2026-01-155.78%13.9M240.3M2.98M

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call0.500.650.950.8210.31318.005.000.916-0.0130.000
call1.000.000.900.3712.8963.000.000.764-0.0100.001
call1.500.001.000.1514.7228.000.000.876-0.0330.000
call2.000.000.050.0217.3507320.000.886-0.0370.000
call2.500.000.200.0912.0731000.000.748-0.0430.001
call5.000.000.050.055.1541.000.000.124-0.0120.000
call7.500.000.050.006.5330.000.000.114-0.0140.000
put0.500.001.000.007.2580.000.00-0.087-0.0120.000
put1.000.000.100.003.0180.000.00-0.209-0.0100.001
put1.500.050.650.306.02517.000.00-0.134-0.0340.000
put2.000.251.250.008.9060.000.00-0.802-0.0080.001
put2.500.751.750.009.1120.000.00-0.831-0.0100.000
put5.001.206.000.000.0000.000.00-0.873-0.0120.000
put7.503.708.500.000.0000.000.00-0.885-0.0130.000

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-1010-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-108-KCurrent report2026-11-10SEC
2026-11-10SCHEDULE 13D/ASEC
2026-09-22EFFECTEffectiveness filing by commission orderSEC
2026-09-22424B3SEC
2026-09-15DEL AMSeparately filed delaying amendment under Securities Act Rule 473 to delay effectiveness of a 1933 Act registration statementSEC
2026-09-14S-3Registration statement for specified transactions by certain issuers including face-amount certificate companiesSEC
2026-09-034Statement of changes in beneficial ownership of securities2026-09-01SEC
2026-09-02144Filing for proposed sale of securities under Rule 144.SEC
2026-08-28SCHEDULE 13D/ASEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-1110-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-118-KCurrent report2026-08-11SEC
2026-08-038-KCurrent report2026-08-03SEC
2026-08-038-KCurrent report2026-07-30SEC
2026-07-014Statement of changes in beneficial ownership of securities2026-06-29SEC
2026-07-014Statement of changes in beneficial ownership of securities2026-06-29SEC
2026-07-014Statement of changes in beneficial ownership of securities2026-06-29SEC
2026-07-014Statement of changes in beneficial ownership of securities2026-06-29SEC
2026-07-014Statement of changes in beneficial ownership of securities2026-06-29SEC
2026-07-014Statement of changes in beneficial ownership of securities2026-06-29SEC
2026-07-014Statement of changes in beneficial ownership of securities2026-06-29SEC
2026-07-014Statement of changes in beneficial ownership of securities2026-06-29SEC
2026-07-014Statement of changes in beneficial ownership of securities2026-06-29SEC
2026-06-298-KCurrent report2026-06-29SEC
2026-06-098-KCurrent report2026-06-05SEC
2026-05-15SCHEDULE 13G/ASEC
2026-05-15SCHEDULE 13G/ASEC
2026-05-1410-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-05-148-KCurrent report2026-05-14SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090015.68K1
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
MAK CAPITAL ONE LLC12.63%
Blackstone Inc.7.70%
Syncona Portfolio Ltd6.25%
ARMISTICE CAPITAL, LLC5.64%
Tetragon Partners GP Ltd3.57%
SCHRODER INVESTMENT MANAGEMENT GROUP2.94%
Frazier Life Sciences Management, L.P.1.67%
BNP Paribas Asset Management Holding S.A.1.26%
Laurion Capital Management LP1.25%
RENAISSANCE TECHNOLOGIES LLC0.75%

Funds

Fund% owned
iShares Biotechnology ETF0.54%
Tema Oncology ETF0.10%
State Street(R) SPDR(R) S&P(R) International Small Cap ETF0.03%
Invesco NASDAQ Future Gen 200 ETF0.02%
ActivePassive International Equity ETF0.01%
Fidelity Nasdaq Composite Index Fund0.01%
Invesco Nasdaq Biotechnology ETF0.00%
ProShares Ultra Nasdaq Biotechnology0.00%
Blackstone Alternative Multi-Strategy Fund-0.01%

OakChart. AUTL. Cached 15 minutes.